In preclinical studies these nanocomplexes were non-toxic and very efficient in different cancer types since they moderated cell viability and hamper mTOR downstream signaling in several xenograft tumor models, including multiple myeloma and breast tumor [82–84]. This evidence concerns the gene MTOR and plasma cell myeloma.